Runtime
Verticalizing LongTermCapabilities’ AI Production Readiness Sprint
Report summary
The best initial commercial vertical is B2B software that embeds AI into regulated, contractual, financial, or operationally sensitive workflows. Legal technology, governance-and-risk software, construction software, and financial-operations software offer the shortest path to a paid engagement beca
Key topics
- Runtime
- AI
- Agentic Web
- Privacy
- Research Archive
- Strategy
- Audit
- Architecture
Research provenance
For citation, use the report title and canonical URL. Archival presence does not establish authorship or promote report statements into portfolio evidence.
Source availability: 29 citation markers in the source export have no recoverable source links. Those markers are omitted from this reader; any supplied bibliography and ordinary links remain. Check the original sources before relying on the cited claims.
This page renders the archived Markdown as safe, formatted HTML. It is background research and does not become a portfolio claim without evidence review.
Full report
On this page
Executive judgment
The best initial commercial vertical is B2B software that embeds AI into regulated, contractual, financial, or operationally sensitive workflows. Legal technology, governance-and-risk software, construction software, and financial-operations software offer the shortest path to a paid engagement because the product team usually owns the deployment, the economic buyer is identifiable, the engagement can be bounded to one product or agent, and procurement is generally less complex than procurement by a hospital, insurer, or bank. Clio, Ironclad, Vanta, Procore, and Ramp are the strongest examples in the researched set.
Healthcare technology is the second-best vertical. Public evidence of production deployment is exceptionally strong, especially around ambient documentation, clinical assistants, autonomous workflows, and member-facing AI. The need for evaluation, traceability, human review, privacy controls, and release evidence is correspondingly strong. However, buyers are more likely to require business-associate terms, clinical review, security assessment, and longer contracting. Abridge, Doximity, athenahealth, Innovaccer, and Omada Health all show substantial production activity, but several also appear to possess sophisticated internal AI teams.
Insurance technology is the third-best vertical. Guidewire and CCC Intelligent Solutions show the clearest combination of embedded AI, governed agent infrastructure, insurance-specific workflows, and active organizational change. The delivery fit is high, but the fastest commercial route is more likely to be through an implementation partner, cloud partner, insurer innovation program, or subcontract arrangement than an unsolicited direct sale to a large platform provider.
The current approximately $20,000 full sprint should remain the commercial center of the offer, not the only package. The recommended ladder is:
| Package | Price hypothesis | Purpose | Delivery model |
|---|---|---|---|
| Executive AI release-decision workshop | $6,500 fixed | Establish whether a specific product or agent is ready for a full evaluation and identify the decisive evidence gaps | 18–20 hours; estimated internal cost $3,060–$3,400; modeled gross margin 48%–53% |
| Production-readiness sprint | $20,000 for B2B SaaS; $22,500–$25,000 for healthcare and insurance | Produce a defensible release recommendation, evaluation evidence, control gaps, and remediation plan | Approximately 70–85 hours for SaaS; 80–95 hours for regulated variants |
| Quarterly AI assurance review | $10,000–$12,000 per review | Re-run critical evaluations after model, prompt, retrieval, tool, policy, or workflow changes | Approximately 28–36 hours; modeled gross margin roughly 46%–60% at the stated cost assumption |
The delivery economics above use a conservative modeled loaded delivery cost of $170 per hour. This is an analyst assumption requiring validation against LongTermCapabilities’ actual opportunity cost, subcontractor cost, non-billable time, insurance, and sales overhead. Under that assumption, a 70–85 hour, $20,000 sprint produces an internal delivery cost of $11,900–$14,450 and gross margin of approximately 28%–41%. The lower end is too thin once sales effort and rework are included; therefore, the offer should have a hard scope cap, paid change control, and a pre-sprint evidence-readiness gate.
The $20,000 price is commercially plausible but is not proven by the public signals. Official postings show that organizations in this market pay approximately $126,000–$190,000 for a Guidewire AI-platform engineer, $178,640–$319,000 for a Samsara staff machine-learning engineer, and $221,000–$290,000 for several Abridge machine-learning and AI-evaluation roles. Those figures support the proposition that scarce AI-production expertise is expensive, but they do not prove that any named organization has budget or intent to retain LongTermCapabilities.
No hiring signal, financing event, risk disclosure, product launch, or governance announcement in this report is treated as proof of distress or buying intent.
Evidence base and analytical boundaries
The research prioritizes organization-controlled sources available through July 31, 2026: company newsrooms, investor-relations filings, official product and documentation pages, public trust centers, and official career pages. A “two-signal” organization has at least two substantively different public indicators—for example, a production product launch plus an AI-governance initiative, an AI product plus a relevant platform job, or a product deployment plus a public evaluation or control program.
NIST’s AI Risk Management Framework provides a credible, non-proprietary operating structure for the offer. The AI RMF is voluntary and is intended to help organizations incorporate trustworthiness considerations into the design, development, use, and evaluation of AI systems. Its Core is organized around Govern, Map, Measure, and Manage. The Generative AI Profile is a cross-sector companion to AI RMF 1.0, while the Playbook supplies suggested actions rather than a mandatory checklist. LongTermCapabilities should therefore describe the sprint as aligned to selected NIST AI RMF and Generative AI Profile outcomes, not as a certification, audit opinion, or declaration of compliance.
Verified public facts
The report verifies product launches, platform changes, public evaluation work, responsible-AI statements, partnerships, public hiring, and risk disclosures only where the organization itself published the information.
Analyst inference
The report infers likely evaluation gaps, buying roles, engagement shapes, procurement paths, and commercial timing from those facts. These inferences are hypotheses to test, not claims about internal conditions.
Unknowns
The most consequential unknowns are each organization’s existing evaluation maturity, current external-adviser relationships, budget ownership, approved-vendor requirements, security-review process, upcoming release dates, and willingness to use a principal-led specialist.
Required human decisions
LongTermCapabilities must decide its minimum acceptable gross margin, whether it will handle protected or production data, whether it carries appropriate professional and cyber insurance, whether clinical subject-matter review is included or client-supplied, and whether it is prepared to sell through partners that may retain 15%–35% of the contract value.
Vertical attractiveness and the shortest path to revenue
| Vertical | Strength of need | Typical bounded entry point | Expected procurement | Competitive reality | Commercial conclusion |
|---|---|---|---|---|---|
| Sensitive-workflow B2B SaaS | High: customer-facing agents touch contracts, compliance evidence, spend, construction records, or enterprise support | One agent, one retrieval workflow, or one release candidate | Approximately 3–8 weeks for direct mid-market work; longer for public-company vendor onboarding | Internal teams are capable, but a focused outside release review can be positioned as independent challenge rather than outsourced engineering | First priority and shortest path |
| Healthcare technology | Very high: clinical or member-facing outputs require accuracy, traceability, human review, privacy, and operational escalation | One clinical workflow, specialty, note type, member interaction, or coding use case | Approximately 6–14 weeks; security, legal, privacy, and clinical review likely | Strong internal AI science at top targets; external value must be architecture-and-assurance integration, not generic responsible-AI advice | Second priority; higher price and stricter boundaries |
| Insurance technology | High: AI affects underwriting, claims, policy interpretation, fraud signals, and core-system workflows | One claims or underwriting agent, one knowledge assistant, or one model gateway | Approximately 8–20 weeks direct; potentially faster through implementation partners | Large partner ecosystems and established consulting firms dominate core-platform work | Third priority; favor partner and subcontract routes |
| Financial services | High, but model-risk, legal, security, and third-party-risk processes lengthen access | Internal agent or customer-facing financial recommendation | Frequently 12–24 weeks or more | Large institutions often have mature model-risk and procurement functions | Select fintech software vendors, not banks, in the first campaign |
| Industrial operations | High consequences, particularly where computer vision affects worker or driver safety | One detection model or operational decision workflow | Often 8–16 weeks | Hardware, edge inference, and site-specific testing increase delivery risk | Pursue only where the sprint excludes physical validation or includes a qualified partner |
| Professional services | Moderate-to-high need but inconsistent product ownership | One internal knowledge or drafting workflow | Potentially 4–10 weeks | Many firms are simultaneously competitors, channel partners, and buyers | Treat mainly as referral and subcontract channels |
The main positioning implication is that “AI readiness” is too broad. The offer should be sold as a release decision for a named production system:
“In three weeks, LongTermCapabilities produces the evidence and executive decision package needed to release, conditionally release, or hold one AI-enabled workflow.”
That promise is clearer than “AI governance consulting” and is less likely to collide with broad transformation programs sold by large consultancies.
The vertical-specific sprint
Sensitive-workflow B2B SaaS
The most compelling version is the AI Agent and Retrieval Release Assurance Sprint.
Required inputs: architecture and data-flow diagrams; model and embedding providers; agent tools and permissions; retrieval sources; tenant-isolation design; prompt and policy configuration; representative production-like test cases; known failure examples; customer-facing claims; logging and tracing design; release and rollback procedures; and applicable contractual or security representations.
Evaluation methods: task-success testing against a labeled scenario set; groundedness and citation correctness; cross-tenant and authorization-boundary tests in a safe test environment; tool-use permission checks; prompt-injection and indirect-injection tests; sensitive-data handling; refusal and escalation behavior; regression testing across model or prompt variants; latency and unit-cost measurement; trace completeness; and failure-mode analysis.
Release criteria: a named accountable owner; an approved use boundary; no critical authorization or cross-tenant failure; acceptable task performance against a documented baseline; traceable source attribution where the product promises grounded answers; human escalation for high-consequence actions; tested rollback; production monitoring; and a signed record of accepted residual risk.
Evidence artifacts: system and data-flow diagram, AI system card, use-case and risk register, test corpus, evaluation harness specification, results report, red-team summary, release-gate checklist, monitoring specification, residual-risk register, remediation backlog, and customer-assurance evidence pack.
Executive deliverable: a concise release / conditional release / hold memorandum that records the decision, unresolved risks, owner, required remediation, and 30/60/90-day actions.
Healthcare technology
The strongest version is the Clinical Workflow AI Release Assurance Sprint.
Required inputs: precise intended use and excluded use; affected clinical or administrative workflow; data provenance; protected-health-information boundaries; model and vendor chain; retention policies; specialty and user populations; note, recommendation, or communication templates; clinical review process; representative de-identified cases; escalation pathways; and post-deployment monitoring plans.
Evaluation methods: clinical task accuracy with client-supplied qualified reviewers; unsupported-statement and omission analysis; evidence linkage; subgroup and specialty slice analysis where sufficient data exists; temporal and medication-context checks; human-review effectiveness; safe-abstention behavior; privacy and retention verification; workflow usability; and replay of realistic edge cases. LongTermCapabilities should not independently determine clinical correctness without qualified client or subcontracted clinical reviewers.
Release criteria: documented intended use; qualified clinical sign-off; no unresolved severe patient-safety failure in the agreed test set; required human review; traceability to source evidence where applicable; prohibited-use enforcement; privacy and retention approval; incident and escalation procedure; rollback; and defined post-release sampling.
Evidence artifacts: clinical-use system card, clinical hazard and control log, evaluation protocol, reviewer rubric, error taxonomy, sample-level trace records, privacy/data-flow map, human-oversight design, release memo, monitoring plan, and evidence package for customer security or clinical-governance review.
Executive deliverable: a joint product–clinical–security decision memo, including which populations and workflows are approved, conditionally approved, or excluded.
Insurance technology
The strongest version is the Claims and Underwriting AI Control Sprint.
Required inputs: workflow and decision rights; agent or model architecture; policy and claims knowledge sources; structured and unstructured data lineage; user roles; automation thresholds; override rules; customer and adjuster notices; model-monitoring design; vendor-model dependencies; and representative scenarios across claim types, policy forms, jurisdictions, and operating teams.
Evaluation methods: policy-grounding and citation tests; consistency across equivalent scenarios; false-positive and false-negative analysis; explanation quality; human-override effectiveness; workflow authorization; audit-trail completeness; drift and change-detection design; adversarial document and prompt testing; and cost/latency analysis.
Release criteria: no critical unauthorized action; defensible source trace; defined automation boundary; effective human override; stable performance across agreed scenario slices; immutable or adequately protected audit records; incident and rollback procedures; and approved residual-risk acceptance.
Evidence artifacts: decision-flow map, agent/model inventory, control matrix, evaluation corpus, release test report, audit-trace examples, override analysis, monitoring thresholds, change-management plan, and executive risk-acceptance memo.
Executive deliverable: a go-live boundary statement specifying what the AI may recommend, draft, or execute; what requires human approval; and what remains prohibited.
Across all three verticals, NIST should be used as the filing structure: Govern for ownership and policy, Map for context and harms, Measure for evaluations and evidence, and Manage for release decisions, monitoring, response, and risk treatment. NIST explicitly describes the Playbook as suggested actions rather than a universal checklist, which supports tailoring the evidence set to each production system.
Ranked action-ready opportunities
The following scoring is ordinal, not probabilistic. Fit, evidence, speed, contract value, and recurrence use 1–5 where 5 is strongest. Delivery risk and access difficulty use 1–5 where 5 is hardest or riskiest.
| Rank | Organization | Fit | Evidence | Speed | Value | Recurrence | Delivery risk | Access difficulty |
|---|---|---|---|---|---|---|---|---|
| 1 | Clio | 5 | 5 | 4 | 4 | 5 | 2 | 3 |
| 2 | Ironclad | 5 | 5 | 4 | 4 | 5 | 2 | 3 |
| 3 | Vanta | 5 | 5 | 4 | 4 | 5 | 2 | 3 |
| 4 | Procore | 5 | 5 | 4 | 4 | 5 | 3 | 3 |
| 5 | Guidewire | 5 | 5 | 2 | 5 | 5 | 3 | 5 |
| 6 | CCC Intelligent Solutions | 5 | 5 | 2 | 5 | 5 | 3 | 4 |
| 7 | Omada Health | 5 | 4 | 3 | 4 | 5 | 4 | 4 |
| 8 | athenahealth | 5 | 5 | 2 | 5 | 5 | 4 | 5 |
| 9 | Innovaccer | 5 | 5 | 2 | 5 | 5 | 4 | 5 |
| 10 | Ramp | 4 | 5 | 3 | 4 | 5 | 3 | 4 |
| 11 | Doximity | 5 | 5 | 2 | 5 | 5 | 5 | 5 |
| 12 | Abridge | 5 | 5 | 2 | 5 | 5 | 5 | 5 |
Candidate commercial profiles
Clio
Verified public facts. Clio announced its Intelligent Legal Work Platform on October 16, 2025, describing platform-wide AI that performs work across legal matters and workflows. The company also publicly states that its Manage AI product does not train models on a firm’s data and limits access to authorized firm information.
Analyst inference. The operating change is a shift from a bounded assistant toward AI executing multi-step legal-work tasks. The likely problem is no longer merely answer quality; it is whether retrieval, authorization, action execution, review, and trace evidence remain reliable across different firm configurations.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Vice President of Engineering, Head of AI, Chief Information Security Officer, General Counsel, and Vice President of Product Trust.
Smallest credible engagement and deliverables. A $6,500 decision workshop focused on one Manage AI workflow, followed by a $20,000 release sprint covering authorization boundaries, matter-level retrieval, groundedness, action confirmation, audit traces, rollback, and customer-assurance artifacts.
Economics. Full sprint: 70–80 hours, modeled internal cost $11,900–$13,600, gross margin 32%–41%. The price is supported as a hypothesis by platform-wide scope and legal-data sensitivity, not by evidence of Clio’s budget.
Sales cycle and route. Estimated 4–8 weeks if sponsored by product or trust leadership; longer if vendor security onboarding is required. Direct or referral route through legal-technology advisers, cloud partners, or law-firm innovation leaders.
Thirty-day validation. Produce a five-page teardown of a single publicly documented Manage AI workflow, map it to a release-evidence checklist, secure three conversations with legal-tech product or trust executives, and seek one paid workshop rather than pitching the full sprint first.
Unknowns and required human decision. Existing internal evaluation depth and adviser relationships are unknown. Stop if Clio already has an independent release-assurance process covering authorization, retrieval, tool use, and customer evidence, or if the requested work requires access to live client matters.
Ironclad
Verified public facts. Ironclad’s December 2025 product briefing described Intake Agent, Redlining Agent, and Conversational Search in early access. Its AI Assist documentation states that the service can operate for customers with business-associate agreements, that Ironclad has a BAA with OpenAI, and that customer data is subject to a contractual “do not train” provision.
Analyst inference. Ironclad is moving from AI-assisted drafting toward agents that interpret intake, alter contract text, and retrieve contract information. Likely risks include playbook fidelity, clause-grounding, tool authority, legal-review escalation, permission inheritance, and evidence for customer procurement teams.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Vice President of AI, Vice President of Engineering, Chief Security Officer, General Counsel, and Head of Product Compliance.
Smallest credible engagement and deliverables. A $6,500 agent-boundary workshop for one early-access agent. Full sprint at $20,000: agent action map, redlining-evaluation corpus, retrieval and citation tests, authorization tests, human-approval design, risk register, release memo, and customer-facing assurance summary.
Economics. 70–85 hours; $11,900–$14,450 modeled internal cost; 28%–41% gross margin. Require a maximum number of contract types and jurisdictions.
Sales cycle and route. Estimated 4–8 weeks direct; referral route through legal-operations consultants, implementation partners, or enterprise customers asking for stronger AI evidence.
Thirty-day validation. Create a contract-redlining evaluation demonstrator using synthetic agreements and a public playbook, then present the methodology—not results about Ironclad—to five CLM implementation partners and two legal-operations communities.
Stop conditions. No-go if the prospect wants legal advice, jurisdiction-wide substantive legal validation, unlimited contract-type testing, or production customer documents without an approved secure environment.
Vanta
Verified public facts. Vanta introduced its AI Agent on June 10, 2025, stating that it guides users, scans programs for inconsistencies, and takes actions while retaining user control. Vanta published AI principles on October 16, 2025 focused on privacy, security, transparency, accuracy, and responsible development. It has since expanded agentic capabilities across policies, questionnaires, risk management, and remediation.
Analyst inference. Vanta’s AI is operating directly inside systems used to create audit and compliance evidence. The most compelling problem is evidence provenance: whether agent-generated policies, questionnaire answers, mappings, and remediation guidance are correctly sourced, appropriately authorized, and resistant to stale or contradictory evidence.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Trust Officer, Chief Information Security Officer, Vice President of Engineering, Head of AI, and Head of Product Compliance.
Smallest credible engagement and deliverables. $6,500 evidence-provenance workshop. $20,000 sprint for one agent workflow including evidence lineage, retrieval accuracy, conflicting-evidence behavior, action authorization, audit-trace completeness, regression pack, release decision, and customer trust artifact.
Economics. 70–80 hours; $11,900–$13,600 cost; 32%–41% gross margin.
Sales cycle and route. Estimated 4–8 weeks. Direct is credible, but an alliance route through audit firms, virtual CISOs, and compliance consultants may create warmer access.
Thirty-day validation. Interview ten Vanta ecosystem consultants about customer objections to AI-generated evidence, then offer one co-branded or subcontracted pilot where the partner retains the customer relationship.
Stop conditions. Stop if the proposed scope duplicates Vanta’s own control-validation function, requires an audit opinion, or cannot distinguish generated evidence from source evidence.
Procore
Verified public facts. Procore has introduced customizable AI agents and Agent Builder for construction workflows such as requests for information, submittals, daily logs, and summaries. It announced a strategic collaboration with AWS on August 26, 2025 to accelerate AI, and in July 2026 announced digital-coworker packages and an expanded pre-built agent library.
Analyst inference. The operating change is from AI search and drafting toward configurable agents that execute project-management work. Likely problems include permission inheritance across projects, stale specifications, conflicting documents, agent-created contractual records, traceability, action confirmation, and safe behavior when project data is incomplete.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Senior Vice President of Engineering, Chief Information Security Officer, Head of AI Platform, Vice President of Product for Procore AI, and Head of Partner Solutions.
Smallest credible engagement and deliverables. $20,000 single-agent sprint focused on an RFI, submittal, or daily-log agent: document hierarchy map, retrieval and conflict tests, role-based authorization evaluation, action-confirmation design, trace schema, release criteria, and customer evidence pack.
Economics. 75–85 hours; $12,750–$14,450 cost; approximately 28%–36% margin. Price should rise to $25,000 if multiple project systems, integrations, or field-workflow validation are included.
Sales cycle and route. Approximately 5–10 weeks direct. Strong alternative routes include AWS, Procore implementation partners, construction-technology consultants, and large contractors piloting Procore AI.
Thirty-day validation. Build a synthetic construction-document conflict set, show how the sprint tests specification hierarchy and agent-generated RFIs, and run five partner interviews plus two contractor innovation interviews.
Stop conditions. No-go if field safety validation, engineering-signoff, unlimited project-document ingestion, or physical-site testing is expected.
Guidewire
Verified public facts. Guidewire’s current insurance-AI platform includes an embedded assistant, developer assistants, and an agentic framework with audit tracing, evaluations, and data protection. Its public job board includes multiple AI roles. A current AI-platform engineering posting describes a secure, governed access point across multiple model providers, with identity controls, observability, incident triage, and production reliability.
Analyst inference. Guidewire is simultaneously building customer-facing insurance agents and an internal governed model gateway. The likely external need is not a foundational AI-RMF workshop; it is independent challenge of a specific agent, release-evidence package, or implementation pattern before customer deployment.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Information Security Officer, Senior Vice President of Cloud Platform, Vice President of Insurance AI, Head of Responsible AI, and Partner Delivery Executive.
Smallest credible engagement and deliverables. A $22,500–$25,000 sprint for one ProNavigator or custom-agent use case: decision-rights map, policy-grounding tests, citation verification, authorization and tool-use tests, human-override analysis, trace review, release memo, and reusable insurer implementation checklist.
Economics. 80–90 hours; $13,600–$15,300 modeled cost; 32%–46% gross margin at $22,500–$25,000.
Sales cycle and route. Direct sales may take 10–20 weeks. The preferred route is subcontract or referral through a Guidewire consulting partner, cloud partner, systems integrator, or insurer already implementing the platform. Guidewire publicly maintains a consulting and technology partner ecosystem.
Thirty-day validation. Identify ten Guidewire partners with AI or ClaimCenter practices, interview five about gaps between platform controls and insurer-specific release evidence, and offer a fixed-scope partner-delivered assurance module.
Stop conditions. Stop direct pursuit without a warm sponsor or partner. No-go if Guidewire requires broad platform certification, proprietary insurer data before contract, or uncompensated partner enablement.
CCC Intelligent Solutions
Verified public facts. CCC announced on April 30, 2025 that AI-based claims-guidance products were being added to third-party casualty workflows, with Medhub for Casualty expected in the third quarter of 2025. On May 8, 2025, CCC announced membership in the World Economic Forum’s AI Governance Alliance. In January 2026 it appointed a chief product officer responsible for scaling AI-driven technology and innovation.
Analyst inference. CCC is extending AI from vehicle and repair estimation into casualty and injury-claims synthesis, where source completeness, explanation, adjuster reliance, consistency, and audit evidence become more consequential.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Data and Analytics Officer, Chief Information Security Officer, General Counsel, Head of AI Governance, and Senior Vice President of Casualty Products.
Smallest credible engagement and deliverables. $25,000 casualty-guidance release sprint: workflow map, source and citation evaluation, omission and contradiction tests, adjuster-override assessment, scenario consistency analysis, trace samples, monitoring thresholds, and executive release boundary.
Economics. 85–95 hours; $14,450–$16,150 cost; gross margin approximately 35%–42% at $25,000.
Sales cycle and route. Approximately 10–20 weeks direct. More credible routes are an insurer customer, casualty-claims consultancy, technology partner, or subcontract relationship.
Thirty-day validation. Conduct six interviews with former or current industry operators through ethical professional networks—not personal-data scraping—using a synthetic casualty-guidance scenario to test whether the proposed evidence artifacts solve an active procurement or release problem.
Stop conditions. No-go if qualified claims, medical, actuarial, or legal reviewers are unavailable; if LongTermCapabilities is asked to opine on claim outcomes; or if the scope spans multiple product lines for the initial fee.
Omada Health
Verified public facts. Omada introduced AI-driven nutritional intelligence in May 2025, launched Meal Map on October 1, 2025, and reported that it had launched both OmadaSpark and Meal Map during 2025. Its resource center also published an August 19, 2025 item describing its approach to safety and security in AI-powered products.
Analyst inference. Omada is incorporating member-facing generative and agentic features alongside human coaches. Likely problems include safe scope of nutritional education, escalation to human care, consistency with clinical content, personalization boundaries, unsupported advice, and post-release sampling.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Medical Officer, Chief Information Security Officer, Vice President of Clinical Product, Head of AI, and Vice President of Quality.
Smallest credible engagement and deliverables. $7,500 clinical-use decision workshop or $25,000 sprint for one member-facing feature. Deliverables include intended-use boundaries, content-grounding tests, escalation evaluation, reviewer rubric, subgroup slices, privacy map, release memo, and monitoring plan.
Economics. 80–90 hours; $13,600–$15,300 cost; 39%–46% margin at $25,000.
Sales cycle and route. Estimated 6–12 weeks. Direct, referral through benefits consultants, or partnership with a clinical-quality adviser.
Thirty-day validation. Develop a synthetic nutrition-assistant evaluation pack reviewed by a paid registered dietitian or qualified clinician, then test the offer in five conversations with digital-health clinical-product leaders.
Stop conditions. Stop if LongTermCapabilities must independently validate medical or nutritional correctness, if no qualified reviewer is funded, or if protected data must leave an approved client environment.
athenahealth
Verified public facts. athenahealth highlighted ambient and generative-AI investments at HIMSS in February 2025. On September 9, 2025 it announced a next-generation AI-native EHR with Chart Assist, and an August 2025 announcement said the company was embedding generative AI across athenaOne. The company has also described infrastructure work to support generative AI and internal employee education.
Analyst inference. The operating change is platform-wide AI deployment inside an EHR and revenue-cycle environment. The probable need is integrated release evidence across clinical documentation, workflow actions, interoperability, billing implications, privacy, and third-party model dependencies.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Medical Officer, Chief Information Security Officer, Vice President of AI, Vice President of Clinical Quality, and General Counsel.
Smallest credible engagement and deliverables. A $25,000 sprint limited to one Chart Assist function, specialty, or workflow: intended-use statement, clinical and administrative test corpus, omission/confabulation analysis, linked-evidence review, human-signoff design, data-flow map, release decision, and monitoring protocol.
Economics. 85–95 hours; $14,450–$16,150 cost; 35%–42% gross margin.
Sales cycle and route. Approximately 10–20 weeks. Referral or subcontract through Microsoft, implementation advisers, healthcare-security consultants, or an athenahealth customer may be faster than direct outreach.
Thirty-day validation. Interview five ambulatory-health IT or clinical-informatics leaders about what evidence they request from AI-enabled EHR vendors, then use those findings to refine the evidence pack and approach a platform partner.
Stop conditions. No-go for an enterprise-wide athenaOne review at this price. Stop if there is no defined specialty, workflow, release candidate, clinical reviewer, or executive decision date.
Innovaccer
Verified public facts. Innovaccer markets an agentic healthcare platform spanning clinical, operational, financial, and contact-center workflows. In April 2025 it introduced a healthcare model-context protocol framed around secure, responsible, and compliant AI. In October 2025 it announced a collaboration using NVIDIA guardrails, inference, speech, and model tooling for production healthcare AI. A 2026 product page describes a Clinical AI Governance Agent for tracking models, guardrails, bias, drift, and regulatory compliance.
Analyst inference. Innovaccer already recognizes the governance problem and is building product capabilities for it. A generic AI-governance sprint would be poorly differentiated. The credible opportunity is an independent release challenge for a specific healthcare agent, or a subcontracted assurance package for Innovaccer customers.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Medical Officer, Chief Information Security Officer, Head of Agent Platform, Head of Clinical AI Governance, and Vice President of Customer Delivery.
Smallest credible engagement and deliverables. $25,000 agent release sprint or a $12,000 partner assurance review. Deliverables: agent/tool map, context and authorization testing, clinical or administrative task evaluations, guardrail validation, audit-trace review, rollback and monitoring criteria, and customer deployment evidence.
Economics. 80–95 hours for a full sprint; $13,600–$16,150 cost; 35%–46% margin at $25,000.
Sales cycle and route. Direct access is difficult. Prioritize NVIDIA, Databricks, AWS, health-system customers, or healthcare implementation partners.
Thirty-day validation. Create a partner-facing statement of work for validating one prior-authorization, contact-center, or referral agent; test it with five healthcare AI implementation leaders and seek one subcontract pilot.
Stop conditions. Do not pitch a broad AI-governance transformation. No-go if the work duplicates Innovaccer’s governance agent, requires evaluation of every agent on the platform, or lacks customer-specific workflow evidence.
Ramp
Verified public facts. Ramp introduced policy-enforcing agents on July 9, 2025, stating that the agents review expenses and escalate cases requiring human judgment. In April 2026 it introduced procurement agents intended to perform sourcing, compliance checks, and negotiation preparation. Ramp has also published guidance on spending and token controls for autonomous agents.
Analyst inference. Ramp’s agents increasingly make or influence financially consequential actions. Likely problems include policy interpretation, authorization, exception handling, audit evidence, vendor-data use, autonomous-purchase limits, token-cost control, and separation of recommendation from execution.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Information Security Officer, Head of AI, Vice President of Engineering, Chief Compliance Officer, and Vice President of Product for Procurement or Expense.
Smallest credible engagement and deliverables. $20,000 sprint for one Policy Agent or procurement workflow: policy test corpus, action and approval map, exception tests, authorization analysis, audit-trace review, cost controls, regression suite, and executive release memo.
Economics. 70–80 hours; $11,900–$13,600 cost; 32%–41% margin.
Sales cycle and route. Estimated 5–10 weeks, but access may be difficult in a high-growth fintech. Direct referral through finance leaders, fintech investors, accounting partners, or procurement advisers is preferable.
Thirty-day validation. Build a synthetic expense-policy benchmark with ambiguous and adversarial receipts, demonstrate an evidence-based release gate, and test it with eight controllers, finance-systems leaders, and fintech product executives.
Stop conditions. Stop if the engagement becomes a financial-controls audit, requires access to real payment credentials, or cannot be isolated to a non-production test environment.
Doximity
Verified public facts. Doximity reported on May 13, 2026 that nearly half of more than 800,000 active prescribers used its clinical AI during the quarter. The company’s Clinical AI Suite includes a clinical assistant and ambient scribe. On the same date, Doximity announced integration of those capabilities with Aledade. On July 15, 2026 it published results from an external clinical-AI safety benchmark and described a physician-review program involving more than 11,000 cited physician experts.
Analyst inference. Doximity has both very large-scale production use and substantial internal evaluation capability. A generic sprint is unlikely to add value. The credible opportunity is independent architecture review of a new integration, an evaluation-methodology challenge, or a customer-specific release package.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Head of Medical AI, Chief Medical Officer, Chief Information Security Officer, Vice President of Platform Engineering, and Head of Clinical Quality.
Smallest credible engagement and deliverables. $25,000 integration-assurance sprint limited to a new partner workflow: data and responsibility map, safety-evaluation gap analysis, integration failure modes, human-review path, trace and citation review, monitoring thresholds, and joint release memo.
Economics. 85–95 hours; $14,450–$16,150 cost; 35%–42% margin.
Sales cycle and route. Approximately 10–20 weeks direct. More credible access is through an integration partner, health-system customer, or clinical-safety research collaborator.
Thirty-day validation. Approach five healthcare-platform partnership leaders with a defined “shared-responsibility evidence pack” for integrations between a clinical AI vendor and a care-delivery platform.
Stop conditions. No action without a specific integration or release boundary. Stop if the prospect expects LongTermCapabilities to outperform or replicate Doximity’s physician-review network.
Abridge
Verified public facts. Abridge announced a broader patient-centered clinician-intelligence platform on June 11, 2026. Its official careers page currently lists machine-learning infrastructure and AI/ML evaluation roles, including a Product Lead for AI/ML evaluations. Abridge also publicly describes its evaluation science and research into confabulation, and in 2024 hired an AI-policy expert to lead legal strategy, public policy, trust, and safety.
Analyst inference. Abridge is one of the most technically mature organizations in the target set. Its need is unlikely to be “build an evaluation program.” A viable engagement would have to address cross-system architecture, new workflow boundaries, independent release challenge, or evidence portability for enterprise health-system customers.
Likely buyer roles. Chief Product Officer, Chief Technology Officer, Chief Scientific Officer, Chief Medical Officer, General Counsel, Head of Trust and Safety, Head of AI Evaluations, and Vice President of Enterprise Platform.
Smallest credible engagement and deliverables. $25,000 independent release challenge for one new workflow or integration: architecture and responsibility map, evaluation-design review, blind-set challenge cases, traceability analysis, human-review effectiveness, release criteria, and enterprise-customer evidence pack.
Economics. 85–95 hours; $14,450–$16,150 cost; 35%–42% gross margin.
Sales cycle and route. Likely 12–24 weeks direct. A health-system customer, electronic-health-record integration partner, insurer, or life-sciences partner is the more credible route.
Thirty-day validation. Test demand among health-system AI-governance leaders for an independent vendor-evidence review that can be applied to Abridge or another ambient-AI vendor, rather than initially selling to Abridge itself.
Stop conditions. Recommend no direct action without a warm introduction and a specific new-product boundary. Do not compete with Abridge’s internal evaluation team or make unsupported claims of clinical certification.
Additional targets and no-action watchlist
These organizations complete the requested set of 25. They are relevant targets for monitoring, partnerships, referrals, or highly specific future engagements, but the current public evidence does not support an immediate direct sprint campaign with acceptable access and differentiation.
| Organization | Public signals | Operating implication | Current recommendation |
|---|---|---|---|
| Fin, formerly Intercom | Fin 3 was announced in October 2025; the company says it expanded its AI research group and renamed itself from Intercom to Fin in 2026. Fin states that it has ISO 42001 and AIUC-1 among its certifications and publicizes extensive trust and reliability controls. | AI is now the company identity and core product, with visible assurance investment | No immediate direct action. Existing assurance maturity makes a generic sprint weak. Explore a referral arrangement or a narrow independent evaluation of a new regulated-industry deployment |
| Zendesk | Zendesk expanded AI agents throughout 2025 and launched a broader Resolution Platform in July 2026. Its trust center reports ISO 42001 and CSA STAR AI assessments, and its AI addendum commits to risk assessment and testing for hallucination and bias. | Strong product and governance maturity | No direct generic offer. Only pursue a customer-specific regulated-workflow evaluation or channel relationship |
| Docusign | Docusign’s FY2025 annual report describes an AI-powered agreement-management platform, and the company has introduced customer controls over data sharing for AI training. | AI is embedded in agreement analysis and management with visible data controls | Monitor. A bounded agent or agreement-analysis release review is plausible, but no second current signal establishes a near-term gap or route |
| ServiceNow | ServiceNow launched AI Control Tower in May 2025 to govern agents, models, and workflows, and published a detailed responsible-AI approach in 2026. | ServiceNow sells the governance platform that a generic sprint might otherwise recommend | No direct pursuit. Explore subcontracting through ServiceNow partners or customer-side implementation assurance |
| Workday | Workday publicly describes an established responsible-AI framework and extended it to agentic AI in March 2026. | Mature internal governance and large-enterprise access barrier | No direct pursuit. Treat Workday implementers and customers as potential channels for customer-side agent assurance |
| Intuit | Intuit expanded GenOS in June and September 2025, including agent-development and evaluation capabilities, and entered a more than $100 million multi-year OpenAI arrangement in November 2025. | Large-scale internal platform and substantial committed investment | No direct action. Internal capability and access difficulty outweigh likely value for a small external sprint |
| Thomson Reuters | Thomson Reuters has continued expanding CoCounsel and in 2026 described a Trust in AI Alliance. It previously reported more than $200 million invested in AI technology in 2024, with a similar pace expected in 2025. | Significant internal investment and mature high-stakes AI positioning | No direct generic pitch. Explore referral, research, or subcontract work through legal and tax implementation partners |
| Samsara | Samsara launched additional AI-powered physical-safety products in June 2025, obtained ISO 42001 certification in October 2025, and continues hiring for AI, edge-ML, evaluation, observability, and production-platform roles. | Strong production evidence, but physical-safety and edge-AI testing increase scope and liability | Partner-only. Pursue a non-physical architecture and evidence review only with explicit exclusions or a qualified safety-testing partner |
| Hinge Health | Hinge Health has described AI-powered computer vision and TrueMotion capabilities and in June 2026 described an AI-powered care model supporting a broader integrated MSK platform. | AI affects movement assessment and care delivery | Monitor. Public control and evaluation signals are insufficient to identify a bounded external gap; physical validation would materially increase delivery risk |
| Teladoc Health | Teladoc announced AI-enabled clinical transcription in March 2025 and has deployed an AI-supported virtual-sitter capability in hospital settings. | AI is present in documentation and inpatient monitoring | No immediate action. Two product signals exist, but a credible route and bounded release candidate are absent; virtual-sitter assurance may require physical and clinical validation beyond the practice’s scope |
| Tempus AI | Tempus announced integration of its generative-AI assistant into Northwestern Medicine’s EHR in September 2025 and has expanded agentic AI for biopharma research. Its filings state that AI, including generative AI, is used across intelligent diagnostics. | AI is core to diagnostics, clinical assistance, and life-sciences products | No direct pursuit. Regulatory, scientific, and access complexity make the $20,000 sprint unlikely to be sufficient without a partner and precise workflow |
| Lemonade | Lemonade identifies itself as an AI-powered insurer, describes rapid AI-enabled claims handling, and discusses the impact of AI regulation and product liability in its public filings. | AI is deeply embedded in underwriting, claims, and customer operations | No direct generic pitch. Core internal capability, regulated decision-making, and public-company procurement make access difficult; consider only a new-agent or EU-release boundary with warm sponsorship |
| Coalition | Coalition added an affirmative AI endorsement to cyber policies in March 2024 and continues publishing on AI-related cyber risks, including agent-amplified attacks. | Strong market relevance, but the verified signals concern insurance coverage and threat analysis more than deployment of a new internal production AI system | No action until a second internal production signal appears. Potential referral partner for AI-security or insured-control work, not yet a primary sprint prospect |
This produces 25 total targets, with substantially more than ten showing two or more independent public signals. The presence of two signals qualifies an organization for research attention, not for an assumption of budget, distress, urgency, or intent.
Market validation plan and required decisions
Recommended campaign sequence
The first 30-day campaign should target sensitive-workflow B2B SaaS, using Clio, Ironclad, Vanta, Procore, and Ramp as named-account research cases while also approaching implementation partners and adjacent companies that resemble them.
During the first week, LongTermCapabilities should finalize one demonstrable evaluation pack for an agent that retrieves sensitive business information and performs an action. The pack should contain synthetic data, a risk register, 25–40 evaluation cases, example traces, release criteria, and a two-page executive decision memo.
During the second week, conduct ten problem interviews: four product or engineering executives, two security or trust executives, two implementation partners, and two customer-side buyers. The interview question is not “Would you buy AI governance?” It is: “What evidence is missing when a customer-facing AI agent is technically complete but not yet approved for release?”
During the third week, offer five paid executive workshops at $6,500. A workshop should be offered only where the prospect can name one system, one decision owner, one target release or expansion, and one unresolved evidence question.
During the fourth week, measure whether the market produces at least one paid workshop, two serious proposal requests, or three partner-led opportunities. Continue only if buyers value the release-decision artifact rather than asking primarily for policy writing, staff augmentation, penetration testing, legal opinions, or broad transformation consulting.
Vertical-specific validation thresholds
For B2B SaaS, continue if at least three of ten interviews identify a live release-evidence problem and at least one buyer will pay for a workshop. Stop if the problem is consistently owned and solved by existing security testing or internal model-evaluation teams.
For healthcare technology, continue only if a clinical reviewer can be client-supplied or profitably subcontracted, a de-identified test process is accepted, and buyers will support a $25,000 starting price. Stop if the market expects enterprise-wide clinical validation at the current $20,000 price.
For insurance technology, continue only if at least two implementation or consulting partners agree that an independent release-evidence module fills a gap in their delivery method. Stop direct outbound if no partner route emerges within 30 days.
Required human decisions before launch
LongTermCapabilities must set a minimum contribution margin. A practical threshold is at least 40% before general overhead; that implies limiting a $20,000 sprint to approximately 70 hours at the modeled $170 hourly cost, raising the regulated sprint price, lowering the true loaded cost, or productizing more of the work.
The practice must decide whether the executive workshop is credited toward the full sprint. The recommended policy is to credit no more than $3,000, because the workshop itself produces a usable decision and consumes principal capacity.
The practice must define data-handling boundaries. The recommended default is synthetic, de-identified, or client-hosted evaluation data, with no production credentials, live patient records, payment credentials, or unrestricted customer documents transferred to LongTermCapabilities.
The practice must define what it will not claim. It should not promise NIST certification, regulatory compliance, clinical safety certification, fairness certification, legal sufficiency, audit assurance, or vulnerability-free operation. The output is an evidence-based architecture and release recommendation aligned to selected NIST outcomes.
The practice must decide its preferred route to market. The evidence favors a mixed model: direct sales to mid-market sensitive-workflow SaaS firms; referral relationships in healthcare; and partner or subcontract routes in insurance and large-enterprise platforms.
The final commercial recommendation is therefore:
Launch the ladder with a $6,500 workshop, retain $20,000 as the tightly scoped B2B SaaS sprint, price healthcare and insurance variants at $22,500–$25,000, and introduce a $10,000–$12,000 quarterly review. Begin with legaltech, GRC, construction software, and financial-operations software. Do not spend initial outbound capacity on highly mature platform companies unless a partner, customer, or specific release boundary creates a credible route.